Early Intra-articular Hyaluronic Acid Injection After Anterior Cruciate Ligament Reconstruction Provides Short-Term Pain Relief and Improves Early Postoperative Function With No Clinical Benefits at 6 and 12 Months: A Randomized Controlled Trial.

IF 4.4 1区 医学 Q1 ORTHOPEDICS
Raghavendra Balagod, Sujit Kumar Tripathy, Siddharth Satyakam Pradhan, Paulson Varghese, Mathan Kumar Ramasubbu, Anand Srinivasan, Gunjar Jain, Mantu Jain
{"title":"Early Intra-articular Hyaluronic Acid Injection After Anterior Cruciate Ligament Reconstruction Provides Short-Term Pain Relief and Improves Early Postoperative Function With No Clinical Benefits at 6 and 12 Months: A Randomized Controlled Trial.","authors":"Raghavendra Balagod, Sujit Kumar Tripathy, Siddharth Satyakam Pradhan, Paulson Varghese, Mathan Kumar Ramasubbu, Anand Srinivasan, Gunjar Jain, Mantu Jain","doi":"10.1016/j.arthro.2025.02.010","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To assess the safety and effectiveness of intra-articular hyaluronic acid (HA) when administered at various time points after arthroscopic anterior cruciate ligament reconstruction (ACLR) surgery.</p><p><strong>Methods: </strong>Ninety patients with anterior cruciate ligament tears undergoing arthroscopic ACLR were divided into 1 of 3 groups: The early HA group received HA on day 2 and saline solution at 2 months, the late HA group received saline solution on day 2 and HA at 2 months, and the placebo group received saline solution at both times. Clinical variables (range of motion [ROM], knee circumference, Lysholm score, International Knee Documentation Committee [IKDC] score, visual analog scale [VAS] score, EQ-5D-5L [EuroQol 5-dimension 5-level questionnaire] score, and Tegner score) and blood parameters (erythrocyte sedimentation rate and C-reactive protein level) were assessed at baseline, monthly up to 6 months, and at 12 months. The synovial tumor necrosis factor α level was measured at baseline, on day 2, and at 3 months.</p><p><strong>Results: </strong>The early HA group showed significantly better ROM than the placebo group (P = .041) and late HA group (P = .029) at 1 and 2 months after surgery. Pain was significantly lower in the early HA group at 1 month compared with the placebo group (P = .033). The early HA group achieved a faster median recovery time to a Lysholm score greater than 83 (P = .01) and had superior Lysholm scores at 2 months. In addition, EQ-5D-5L and IKDC scores were significantly better at 1 and 2 months in the early HA group. There were no differences in erythrocyte sedimentation rate and C-reactive protein level between the groups at any follow-up. However, both HA groups showed a significant decrease in tumor necrosis factor α level from baseline (P < .05). No adverse events were reported. The minimal clinically important difference (MCID) for the VAS score at 1 month was achieved by 93.3%, 60.7%, and 65.5% of participants in the early HA group, late HA group, and placebo group, respectively (P < .01). However, no significant differences were observed between the groups in the percentage of patients achieving the MCID for the VAS score at 1 year or the MCIDs for the IKDC and Lysholm scores at 1 month, 2 months, and 1 year.</p><p><strong>Conclusions: </strong>Early intra-articular HA injection after ACLR effectively reduced pain and improved ROM during the early postoperative period, leading to enhanced functional outcomes and quality of life. However, these benefits were not sustained beyond 2 months, and no clinical benefits were noted at 6- and 12-month follow-up. The treatment was found to be safe and well tolerated for postoperative use. Notably, there was no significant difference in the number of patients achieving the MCIDs for functional scores, except for pain at 1 month.</p><p><strong>Level of evidence: </strong>Level I, double-blind randomized controlled study.</p>","PeriodicalId":55459,"journal":{"name":"Arthroscopy-The Journal of Arthroscopic and Related Surgery","volume":" ","pages":""},"PeriodicalIF":4.4000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arthroscopy-The Journal of Arthroscopic and Related Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.arthro.2025.02.010","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To assess the safety and effectiveness of intra-articular hyaluronic acid (HA) when administered at various time points after arthroscopic anterior cruciate ligament reconstruction (ACLR) surgery.

Methods: Ninety patients with anterior cruciate ligament tears undergoing arthroscopic ACLR were divided into 1 of 3 groups: The early HA group received HA on day 2 and saline solution at 2 months, the late HA group received saline solution on day 2 and HA at 2 months, and the placebo group received saline solution at both times. Clinical variables (range of motion [ROM], knee circumference, Lysholm score, International Knee Documentation Committee [IKDC] score, visual analog scale [VAS] score, EQ-5D-5L [EuroQol 5-dimension 5-level questionnaire] score, and Tegner score) and blood parameters (erythrocyte sedimentation rate and C-reactive protein level) were assessed at baseline, monthly up to 6 months, and at 12 months. The synovial tumor necrosis factor α level was measured at baseline, on day 2, and at 3 months.

Results: The early HA group showed significantly better ROM than the placebo group (P = .041) and late HA group (P = .029) at 1 and 2 months after surgery. Pain was significantly lower in the early HA group at 1 month compared with the placebo group (P = .033). The early HA group achieved a faster median recovery time to a Lysholm score greater than 83 (P = .01) and had superior Lysholm scores at 2 months. In addition, EQ-5D-5L and IKDC scores were significantly better at 1 and 2 months in the early HA group. There were no differences in erythrocyte sedimentation rate and C-reactive protein level between the groups at any follow-up. However, both HA groups showed a significant decrease in tumor necrosis factor α level from baseline (P < .05). No adverse events were reported. The minimal clinically important difference (MCID) for the VAS score at 1 month was achieved by 93.3%, 60.7%, and 65.5% of participants in the early HA group, late HA group, and placebo group, respectively (P < .01). However, no significant differences were observed between the groups in the percentage of patients achieving the MCID for the VAS score at 1 year or the MCIDs for the IKDC and Lysholm scores at 1 month, 2 months, and 1 year.

Conclusions: Early intra-articular HA injection after ACLR effectively reduced pain and improved ROM during the early postoperative period, leading to enhanced functional outcomes and quality of life. However, these benefits were not sustained beyond 2 months, and no clinical benefits were noted at 6- and 12-month follow-up. The treatment was found to be safe and well tolerated for postoperative use. Notably, there was no significant difference in the number of patients achieving the MCIDs for functional scores, except for pain at 1 month.

Level of evidence: Level I, double-blind randomized controlled study.

一项随机对照试验:前交叉韧带重建后早期关节内透明质酸注射可短期缓解疼痛并改善术后早期功能,但在6个月和12个月时没有临床益处。
目的:本随机对照试验评估关节镜前交叉韧带重建(ACLR)手术后不同时间点给予关节内透明质酸(IAHA)的安全性和有效性。方法:90例行关节镜下ACLR的前交叉韧带撕裂患者分为3组:早期HA组第2天给予HA, 2个月时给予生理盐水;HA晚期组第2天给予生理盐水,第2个月给予HA;安慰剂组两次均给予生理盐水治疗。临床(活动范围- rom、膝围、Lysholm评分、IKDC、VAS、EQ5D5L、Tegner评分)和血液参数(血液ESR和CRP)在基线、每月至6个月和12个月进行评估。在基线、第2天和第3个月时测量滑膜tnf - α水平。结果:术后1、2个月,早期HA组的ROM明显优于安慰剂组(P=0.041)和晚期HA组(P=0.029)。与安慰剂组相比,早期HA组在1个月时疼痛明显降低(P=0.033)。早期HA组的Lysholm评分中位恢复更快(P=0.01), 2个月时Lysholm评分更高。早期HA组在1个月和2个月时EQ5D5L和IKDC评分也明显改善。在任何随访中,两组之间的血液ESR和CRP水平均无差异。然而,两个HA组的tnf - α均较基线显著下降(结论:ACLR术后早期注射IAHA可有效减轻疼痛,改善术后早期ROM,提高功能结局和生活质量。然而,这些益处没有持续超过2个月,在6个月和12个月的随访中没有发现临床益处。术后使用该治疗方法安全且耐受性良好。值得注意的是,除了一个月的疼痛外,在功能评分中达到MCID的患者数量没有显著差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
9.30
自引率
17.00%
发文量
555
审稿时长
58 days
期刊介绍: Nowhere is minimally invasive surgery explained better than in Arthroscopy, the leading peer-reviewed journal in the field. Every issue enables you to put into perspective the usefulness of the various emerging arthroscopic techniques. The advantages and disadvantages of these methods -- along with their applications in various situations -- are discussed in relation to their efficiency, efficacy and cost benefit. As a special incentive, paid subscribers also receive access to the journal expanded website.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信